Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 10
Submit an article Journal homepage
486
Views
49
CrossRef citations to date
0
Altmetric
Reviews

Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases

Puneet Chopra Ranbaxy Research Laboratories, Department of Pharmacology, New Drug Discovery Research, Plot No-20, Sector-18, Gurgaon-122001-Haryana, India +91 124 2342001 10, ext. 5265; +91 124 2343544; [email protected]
, PhD,
Vijay Kanoje Ranbaxy Research Laboratories, Department of Pharmacology, New Drug Discovery Research, Plot No-20, Sector-18, Gurgaon-122001-Haryana, India +91 124 2342001 10, ext. 5265; +91 124 2343544; [email protected]
, MPharma,
Arvind Semwal Ranbaxy Research Laboratories, Department of Pharmacology, New Drug Discovery Research, Plot No-20, Sector-18, Gurgaon-122001-Haryana, India +91 124 2342001 10, ext. 5265; +91 124 2343544; [email protected]
, MPharma &
Abhijit Ray Ranbaxy Research Laboratories, Department of Pharmacology, New Drug Discovery Research, Plot No-20, Sector-18, Gurgaon-122001-Haryana, India +91 124 2342001 10, ext. 5265; +91 124 2343544; [email protected]
, PhD
Pages 1411-1425 | Published online: 22 Sep 2008

Bibliography

  • Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-26
  • Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-83
  • Hale KK, Trollinger D, Rihanek M, Manthey CL. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J Immunol 1999;162:4246-52
  • Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004;4:372-7
  • Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999;1:94-7
  • Mudgett JS, Ding J, Guh-Siesel L, et al. Essential role for p38alpha mitogen- activated protein kinase in placental angiogenesis. Proc Natl Acad Sci USA 2000;97:10454-9
  • Engelman JA, Lisanti MP, Scherer PE. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J Biol Chem 1998;273:32111-20
  • Zetser A, Gredinger E, Bengal E. p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor. J Biol Chem 1999;274:5193-200
  • Li Y, Jiang B, Ensign WY, et al. Myogenic differentiation requires signalling through both phosphatidylinositol 3-kinase and p38 MAP kinase. Cell Signal 2000;12:751-7
  • Wu Z, Woodring PJ, Bhakta KS. p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol Cell Biol 2000;20:3951-64
  • Suelves M, Lluis F, Ruiz V, et al. Phosphorylation of MRF4 transactivation domain by p38 mediates repression of specific myogenic genes. EMBO J 2004;23:365-75
  • De Angelis L, Zhao J, Andreucci JJ, et al. Regulation of vertebrate myotome development by the p38 MAP kinase-MEF2 signaling pathway. Dev Biol 2005;283:171-9
  • Jones NC, Tyner KJ, Nibarger L, et al. The p38alpha/beta MAPK functions as a molecular switch to activate the quiescent satellite cell. J Cell Biol 2005;169:105-16
  • Ziegler-Heitbrock HW, Blumenstein M, Käfferlein E, et al. In vitro desensitization to lipopolysaccharide suppresses tumour necrosis factor, interleukin-1 and interleukin-6 gene expression in a similar fashion. Immunology 1992;75:264-8
  • Molnár A, Theodoras AM, Zon LI, Kyriakis JM. Cdc42Hs, but not Rac1, inhibits serum-stimulated cell cycle progression at G1/S through a mechanism requiring p38/RK. J Biol Chem 1997;272:13229-35
  • Takenaka K, Moriguchi T, Nishida E. Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. Science 1998;280:599-602
  • Shiozaki K, Russell P. Cell-cycle control linked to extracellular environment by MAP kinase pathway in fission yeast. Nature 1995;378:739-43
  • Kummer JL, Rao PK, Heidenreich KA. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem 1997;272:20490-4
  • Xia Z, Dickens M, Raingeaud J, et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31
  • Juo P, Kuo CJ, Reynolds SE, et al. Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Mol Cell Biol 1997;17:24-35
  • Cahill MA, Peter ME, Kischkel FC, et al. CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases. Oncogene 1996;13:2087-96
  • Cardone MH, Salvesen GS, Widmann C, et al. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell 1997;90:315-23
  • Huang S, Jiang Y, Li Z, et al. Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity 1997;6:739-649
  • Schwenger P, Bellosta P, Vietor I, et al. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA 1997;94:2869-73
  • Kawasaki H, Morooka T, Shimohama S, et al. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J Biol Chem 1997;272:18518-21
  • Yue TL, Ni J, Romanic AM, et al. TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. J Biol Chem 1999;274:1479-86
  • Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997;15:2169-77
  • Heit B, Tavener S, Raharjo E, Kubes P. An intracellular signaling hierarchy determines direction of migration in opposing chemotactic gradients. J Cell Biol 2002;159:91-102
  • Heuertz RM, Tricomi SM, Ezekiel UR, Webster RO. C-reactive protein inhibits chemotactic peptide-induced p38 mitogen-activated protein kinase activity and human neutrophil movement. J Biol Chem 1999;274:17968-74
  • Ishizuka T, Okajima F, Ishiwara M, et al. Sensitized mast cells migrate toward the antigen: a response regulated by p38 mitogenactivated protein kinase and Rho-associated coiled-coil-forming protein kinase. J Immunol 2001;167:2298-304
  • Rousseau S, Dolado I, Beardmore V, et al. CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK–MAPKAP-K2–HSP27 pathway, Cell Signal 2006;18:1897-905
  • Hedges JC, Dechert MA, Yamboliev IA, et al. A role for p38(MAPK)/HSP27 pathway in smooth muscle cell migration. J Biol Chem 1999;274:24211-9
  • Piotrowicz RS, Hickey E, Levin EG. Heat shock protein 27 kDa expression and phosphorylation regulates endothelial cell migration. FASEB J 1998;12:481-90
  • Simon C, Goepfert H, Boyd D. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res 1998;58:1135-9
  • Simon C, Simon M, Vucelic G, et al. The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation. Exp Cell Res 2001;271:344-55
  • Woo CH, Lim JH, Kim JH. Lipopolysaccharide induces matrix metalloproteinase-9 expression via a mitochondrial reactive oxygen species-p38 kinase-activator protein-1 pathway in Raw 264.7 cells. J Immunol 2004:173:6973-80
  • Nguyen J, Gogusev J, Knapnougel P, Bauvois B. Protein tyrosine kinase and p38 MAP kinase pathways are involved in stimulation of matrix metalloproteinase-9 by TNF-alpha in human monocytes. Immunol Lett 2006;106:34-41
  • Saccani S, Pantano S, Natoli G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol 2002;3:69-75
  • Soloaga A, Thomson S, Wiggin GR, et al. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J 2003;22:2788-97
  • Perregaux DG, Dean D, Cronan M, et al. Inhibition of interleukin-1 beta production by SKF86002: evidence of two sites of in vitro activity and of a time and system dependence. Mol Pharmacol 1995;48:433-42
  • Guan Z, Buckman SY, Pentland AP, et al. Induction of Cyclooxygenase-2 by the Activated Mekk1-] Sek1/Mkk4-]P38 Mitogen-Activated Protein Kinase Pathway. J Biol Chem 1998;273:12901-8
  • Badger AM, Cook MN, Lark MW, et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol 1998;161:467-73
  • Feng GJ, Goodridge HS, Harnett MM, et al. Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J Immunol 1999;163:6403-12
  • Clark AR, Dean JL, Saklatvala J. Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. FEBS Lett 2003;546:37-44
  • Reunanen N, Li SP, Ahonen M, et al. Activation of p38 alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. J Biol Chem 2002;277:32360-8
  • Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43:2501-12
  • Lee SJ, Kavanaugh A. Pharmacological treatment of established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:811-29
  • Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-5
  • Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-31
  • Wei S, Kitaura H, Zhou P, et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005;115:282-90
  • Matsumoto M, Sudo T, Saito T, et al. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 2000;275:31155-61
  • Foster ML, Halley F, Souness JE. Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect 2000;13:488-97
  • Branger J, Van Den Blink B, Weijer S, et al. Antiinflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002;168:4070-7
  • Barnes PJ. Novel Approaches and Targets for Treatment of Chronic Obstructive Pulmonary Disease Am. J Respir Crit Care Med 1999;160:S72-9
  • Elias JA, Lee CG, Zheng T, et al. New insights into the pathogenesis of asthma. J Clin Invest 2003;111:291-7
  • Herrick CA, Bottomly K. To respond or not to respond: t cells in allergic asthma. Nat Rev Immunol 2003;3:405-12
  • Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev 1999;51:213-340
  • Kawakami T, Galli SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2002;2:773-86
  • Adachi T, Choudhury BK, Stafford S, et al. The differential role of extracellular signal-regulated kinases and p38 mitogen-activated protein kinase in eosinophil functions. J Immunol 2000;165:2198-204
  • Wong CK, Ip WK, Lam CW. Interleukin-3, -5, and granulocyte macrophage colony-stimulating factor-induced adhesion molecule expression on eosinophils by p38 mitogen-activated protein kinase and nuclear factor-[kappa] B. Am J Respir Cell Mol Biol 2003;29:133-47
  • Hallsworth MP, Moir LM, Lai D, Hirst SJ. Inhibitors of mitogen-activated protein kinases differentially regulate eosinophil-activating cytokine release from human airway smooth muscle. Am J Respir Crit Care Med 2001;164:688-9
  • Underwood DC, Osborn RR, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L895-902
  • Duan W, Chan JH, McKay K, et al. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 2005;171:571-8
  • Available from: http://www.arraybiopharma.com
  • Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-2
  • Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008;31:62-9
  • Underwood DC, Osborn RR, Kotzer CJ, et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 2000;293:281
  • Medicherla S, Fitzgerald MF, Spicer D, et al. p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 2008;324:921-9
  • Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000;12:1-13
  • Tibbles LA, Woodgett JR. The Stress-activated protein kinase pathways. Cell Mol Life Sci 1999;55:1230-54
  • Van Den Blink B, Juffermans NP, Ten Hove T, et al. p38 Mitogen-activated protein kinase inhibition increases cytokine release by macrophages in vitro and during infection in vivo. J Immunol 2001;166:582-7
  • Lehner MD, Schwoebel F, Kotlyarov A, et al. Mitogen-activated protein kinase-activated protein kinase-2 deficient mice show increased susceptibility to Listeria monocytogenes infection. J Immunol 2002;168:4667-73
  • Culy CR, Keating GM. Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis, and juvenile rheumatoid arthritis. Biodrugs 2003;17:139-45
  • Kavanaugh A, Cush JJ. FDA meeting: update on the safety of new drugs for rheumatoid arthritis. Part II. Chf, infection, and other safety issues. Hotline August 2003, Available from: http://www.rheumatology.org/publications/hotlin
  • Centrella M, McCarthy TL, Canalis E, et al. Mitogenesis in fetal rat bone cells simultaneously exposed to type beta transforming growth factor and other growth regulators. FASEB J 1987;1:312-7
  • Zhen X, Wei L, Wu Q, et al. Mitogen-activated protein kinase p38 mediates regulation of chrondrocyte differentiation by parathyroid hormone. J Bio Chem 2001;272:4879-85
  • Guicheux J, Lemonnier J, Ghayor C, et al. Activation of p38 mitogen-activated protein kinase and c-jun-nh2-terminal kinase by bmp2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 2003;18:2060-8
  • Wride MA, Sanders EJ. Potential roles for tumor necrosis factor alpha during embryonic development. Anat Embryol 1995;191:1-10
  • Hill JA. Cytokines considered critical in pregnancy. Am J Reprod Immunol 1992;28:123-6
  • Sugden PH, Clerk A. “Stress-responsive” mitogen-activated protein kinases (c-jun n-terminal kinases and p38 mitogen- activated protein kinases) in the myocardium. Circ Res 1998;83:345-52
  • Ravingerova T, Barancik M, Strniskova M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 2003;247:127-38
  • Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999;99:1685-91
  • Lemke LE, Bloem LJ, Fouts R, et al. Decreased p38 MAPK activity in end-stage failing human myocardium: p38 mapk alpha is the predominant isoform expressed in human heart. J Mol Cell Cardiol 2001;33:1527-40
  • Liang Q, Molkentin JD. Redefining the roles of p38 and Jnk signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol 2003;35:1385-94
  • Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46
  • Behr TM, Berova M, Doe CP, et al. p38 Mitogen-Activated Protein Kinase Inhibitors for the Treatment of Chronic Cardiovascular Disease. Curr Opin Invest Drugs 2003;4:1059-64
  • Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38a protein. Curr Med Chem 2005;12;2979-94
  • Hynes J, Leftheris K. Small molecule p38 inhibitors: novel structure features and advances from 2002 – 2005. Curr Top Med Chem 2005;5:967-85
  • Goldstein DM, Gabriel T. Pathway to the clinic: inhibition of p38 MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem 2005;5:1017-29
  • Wrobleski ST, Doweyko AM. Structural comparison of p38 inhibitor–protein complexes: a review of recent p38 inhibitors having unique binding interactions. Curr Top Med Chem 2005;5:1005-16
  • Allen M, Svensson L. Deficiency of the stress kinase 38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med 2000;191:859-70
  • Dambach DM. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 2005;5:929-39
  • Everard ML, Hardy JG, Milner AD. Comparison of nebulised aerosol deposition in the lungs of healthy adults following oral and nasal inhalation. Thorax 1993;48:1045-6
  • Scheuch G, Stahlhofen W. Deposition and dispersion of aerosols in the airways of the human respiratory tract: the effect of particle size. Exp Lung Res 1992;18:343-58
  • Ahrens RC, Ries RA, Popendorf W, Wiese JA. The delivery of therapeutic aerosols through endotracheal tubes. Pediatr Pulmonol 1986;2:19-26
  • Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: An update. Pharmacol Rev 1998;50:515-96
  • Bond JA. Metabolism and elimination of inhaled drugs and airborne chemicals from the lungs. Pharmacol Toxicol 1993;72:36-47
  • Reed CJ. Drug metabolism in the nasal cavity: relevance to toxicology. Drug Metab Rev 1993;25:173-205
  • Wolff RK, Dorato MA. Toxicologic testing of inhaled pharmaceutical aerosols. Crit Rev Toxicol 1993;23:343-69

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.